Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.drudis.2020.11.025 http://scihub22266oqcxt.onion/10.1016/j.drudis.2020.11.025 33253920!7694556!33253920     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 263.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 263.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Drug+Discov+Today 2021 ; 26 (2): 593-603 Nephropedia Template TP {{tp|p=33253920|t=2021. Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic |pdf=|usr=}}{{33253920}} gab.com Text Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic JO: Drug Discov Today http://www.kidney.de/pget.php?&tw=1&pmid=33253920 #FOAvip The US Food and Drug Administration (FDA) Expanded Access (EA) Program, which allows for compassionate uses of unapproved therapeutics and diagnostics outside of clinical trials, has gained significant traction during the Coronavirus 2019 (COVID-19) pandemic. While development of vaccines has been the major focus, uncertainties around new vaccine safety and effectiveness have spawned interest in other pharmacological options. Experimental drugs can also be approved under the FDA Emergency Use Authorization (EUA) program, designed to combat infectious disease and other threats. Here, we review the US experience in 2020 with pharmacological EA and EUA approvals during the pandemic. We also provide a description of, and clinical rationale for, each of the EA- or EUA-approved drugs (e.g. remdesivir, convalescent plasma, propofol 2%, hydroxychloroquine, ruxolitinib, bamlanivimab, baricitinib, casirivimab plus imdevimab) during the pandemic and concluding reflections on the EA program and its potential future uses. Twit Text FOAVip Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic ????Drug Discov Today http://www.kidney.de/pget.php?&tw=1&pmid=33253920 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33253920 #FOAvip English Wikipedia <ref>{{Cite pmid|33253920}}</ref> Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic #MMPMID33253920 Rizk JG; Forthal DN; Kalantar-Zadeh K; Mehra MR; Lavie CJ; Rizk Y; Pfeiffer JP; Lewin JC Drug Discov Today 2021[Feb]; 26 (2): 593-603 PMID33253920show ga The US Food and Drug Administration (FDA) Expanded Access (EA) Program, which allows for compassionate uses of unapproved therapeutics and diagnostics outside of clinical trials, has gained significant traction during the Coronavirus 2019 (COVID-19) pandemic. While development of vaccines has been the major focus, uncertainties around new vaccine safety and effectiveness have spawned interest in other pharmacological options. Experimental drugs can also be approved under the FDA Emergency Use Authorization (EUA) program, designed to combat infectious disease and other threats. Here, we review the US experience in 2020 with pharmacological EA and EUA approvals during the pandemic. We also provide a description of, and clinical rationale for, each of the EA- or EUA-approved drugs (e.g. remdesivir, convalescent plasma, propofol 2%, hydroxychloroquine, ruxolitinib, bamlanivimab, baricitinib, casirivimab plus imdevimab) during the pandemic and concluding reflections on the EA program and its potential future uses. |*Antiviral Agents/classification/pharmacology[MESH] |*COVID-19 Drug Treatment[MESH] |*COVID-19/epidemiology/prevention & control[MESH] |*Compassionate Use Trials/methods/trends[MESH] |COVID-19 Vaccines/*pharmacology[MESH] |Drug Approval[MESH] |Humans[MESH] |SARS-CoV-2[MESH]Expanded Access Programs, compassionate drug use, and Emergency Use A(epmc).pdf DeepDyve Pubget Overpricing